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spasm segments compared to non-spasm segments (0.31  0.58 mm2
vs. 0.04  0.01 mm2, p ¼ 0.046). In spasm segments, thrombus was
most frequently located at spasm sites (81%) followed by upstream of
the spasm segments (19%). Thin cap ﬁbroatheroma was mainly seen in
non-spasm segments compared to spasm segments (21.6% vs. 4.7% vs.
p ¼ 0.038). Plaque erosion however, was more prevalent at spasm






(n [ 46) p-valuePlaque Erosion 23 (18.7) 20 (26.0) 3 (6.5) 0.008Location of erosion 0.086Proximal to analyzed site 6 (26.1) 4 (20.0) 2 (66.6)At vasospasm/analyzed site 17 (73.9) 16 (80.0) 1 (33.3)Thrombus 25 (20.3) 21 (27.3) 4 (8.7) 0.019Red thrombus 4 (16.0) 4 (19.0) 0White thrombus 21 (84.0) 17 (81.0) 4 (100.0)Location of thrombus 0.053Proximal to analyzed site 7 (28.0) 4 (19.0) 3 (75.0)At vasospasm/analyzed site 18 (72.0) 17 (81.0) 1 (25.0)Size of thrombusArea of thrombus (mm2) 0.27  0.54 0.31  0.58 0.04  0.01 0.046
Maximal diameter of thrombus (mm) 0.63  0.53 0.68  0.56 0.39  0.08 0.037CONCLUSIONS Compared to non-spasm segments, thrombus and
plaque erosion were more common at spasm segments. These ﬁndings
suggest the potential beneﬁt and treatment role of antiplatelet ther-
apy in VSA.
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BACKGROUND Several investigations revealed that daily glucose
ﬂuctuation has adverse effects on endothelial cells. Moreover, we
reported that it may have an independent contributing factor on
coronary plaque vulnerability. Little is known, however, about its
impact on neointimal growth after stenting in coronary artery disease
(CAD) patients. We aimed to investigate the impact of glucose ﬂuc-
tuation on neointimal growth following everolimus-eluting stent
(EES) implantation.
METHODS This prospective study enrolled 70 consecutive CAD pa-
tients pretreated with adequate lipid-lowering therapy. 46 patients of
them underwent 8-month follow-up optical coherence tomography
after EES implantation. Glucose ﬂuctuation, expressed as mean
amplitude of glycemic excursion (MAGE) was determined by contin-
uous glucose monitoring before percutaneous coronary intervention.
Uniformity of neointimal distribution was evaluated in 3-D by
computing mean neointimal thickness (NIT) within 360 equally
spaced radial sectors for every 1-mm cross-section by OCT analysis 8
months after stenting. In addition, we analyzed % of uncovered struts
at OCT follow-up. No changes were made to any of the medications for
the control of diabetes, lipids, and hypertension.
RESULTS In total, 56 stents were evaluated in 46 patients. MAGE was
signiﬁcantly correlated with maximum NIT and standard deviation of
NIT, representing the roughness of neointima within a whole stent
(Figure). Moreover, higher MAGE was signiﬁcantly associated with the
higher percentage of uncovered struts (Figure). Multiple linear
regression analysis showed MAGE had independently association
with % of uncovered struts and standard deviation of NIT
(standardized coefﬁcient b ¼ 0.566 and 0.381, respectively, both
P < 0.005).CONCLUSIONS Glucose ﬂuctuation may impact the vessel healing
after EES implantation in CAD patients receiving adequate lipid-
lowering therapy. Further investigations should address the rationale
for the early detection and control of glucose ﬂuctuation in the era of
universal statin use for CAD patients.
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BACKGROUND Mechanical properties of a fully bioresorbable poly-
lactide scaffold are inherently different from a permanent metallic
stent. A previous retrospective intravascular ultrasound (IVUS) study
suggested that immediately after the procedure the Absorb scaffold
was more eccentric and asymmetric when compared to a Xience stent.
However, the relationship between the IVUS parameters and clinical
events has not been investigated in the context of a randomized trial.
METHODS In the ABSORB II trial comparing the Absorb scaffold and
the Xience stent in treatment for a de novo coronary artery stenosis,
protocol-mandated IVUS imaging was performed post procedure in
485 patients with 506 lesions (2:1 randomization, Absorb: 330, Xience:
176). The eccentricity index (EI) was calculated as a minimal value of
the quotients (computed per cross section) of the projected minimum
diameter and the projected maximal diameter. The asymmetry index
(AI) was calculated per lesion as (1 –minimum diameter / maximal
diameter throughout a pullback). The stented /scaffold lesions were
categorized into three groups: 1) concentric and symmetric (EI  0.7
[MUSIC criterion] and AI  0.3); 2) concentric and asymmetric (EI  0.7
and AI > 0.3); 3) eccentric and asymmetric (EI < 0.7 and AI > 0.3).
RESULTS The overall results are presented in the Figure. Post-pro-
cedural EI was smaller in the Absorb arm than in the Xience arm
(0.740.07 vs. 0.810.05, p<0.001), while AI was greater in the
Absorb arm (0.330.08 vs. 0.270.06, p<0.001). At 1-year, the MACE
rates were 8.2%, 6.0% and 2.3% in “eccentric/asymmetric” group, the
“concentric/asymmetric” group and the “concentric/symmetric”
group , respectively (p¼0.04).
